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Abstract 
Background: Living in a larger city is associated with increased risk of schizophrenia; and world-wide, 
consistent evidence shows that the higher the degree of urbanicity the higher the risk of schizophrenia. 
However, the association between urbanicity and treatment-resistant schizophrenia (TRS) as a more 
severe form of schizophrenia or separate entity of schizophrenia has not been fully explored yet. 
We aimed to investigate the association between urbanicity and incidence of TRS. 
Methods: A large Danish population-based cohort of all individuals with a first schizophrenia diagnosis 
after 1996 was followed until 2013 applying survival analysis techniques. TRS was assessed using a 
treatment-based proxy, defined as the earliest observed instance of either clozapine initiation or hospital 
admission due to schizophrenia after having received two prior antipsychotic monotherapy trials of 
adequate duration. 
Results: Among the 13,349 schizophrenia patients, 17.3% experienced TRS during follow-up (median 
follow-up 7 years, inter-quartile range: 3-12 years). The 5-year risk of TRS ranged from 10.5% in the 
capital area to 17.6% in the rural areas. Compared with individuals with schizophrenia residing in the 
capital area, hazard ratios were 1.44 (1.31-1.59) for provincial areas and 1.60 (1.43-1.79) for rural areas.  
Conclusion: Higher rates of TRS were found in less urbanized areas. The different direction of urban-
rural differences regarding TRS and schizophrenia risk may indicate urban-rural systematic differences in 
treatment practices or different urban-rural etiologic types of schizophrenia.  
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1 Introduction 
The association between urbanicity and schizophrenia has been extensively studied, and consistently an 
increased incidence of schizophrenia has been observed at higher levels of urbanicity (March et al., 2008; 
Pedersen and Mortensen, 2001b; Vassos et al., 2012; Vassos, 2015). This finding was invariant to the 
definition used for urban exposure (population size or density); whether urbanicity was determined at 
birth, upbringing, schizophrenia diagnosis, or interview; and whether based on cohort or cross-sectional 
study designs ( March et al., 2008; Pedersen, 2006, 2015; Pedersen and Mortensen, 2001a; Torrey et al., 
1997). 
Treatment resistant schizophrenia (TRS) is generally defined as not responding adequately to treatment 
despite at least two first-line antipsychotic treatments. It is a clinically relevant complication of the course 
of schizophrenia affecting approximately 30% of all persons with schizophrenia. TRS is burdened with 
heavy reductions in life quality and high costs of medication and health services (Barnes, 2011; Kennedy 
et al., 2013).  
It is debated whether TRS merely constitutes the most severe end of spectrum of schizophrenia or if it 
defines a distinct subtype of schizophrenia. The latter may suggest a different etiology of TRS than of 
schizophrenia; in that sense, urbanicity would be hypothesized to act differently in TRS. This hypothesis 
was supported by a recent study reporting an increased incidence of TRS at lower levels of urbanicity 
compared to higher levels of urbanicity (Wimberley et al., 2016). This association merits closer 
investigation in an etiological setting adjusting for an appropriately chosen set of confounders and 
evaluating its temporal association. This could help elucidate the nature and course of schizophrenia and 
predict TRS. A better understanding of urban-rural differences in TRS may be helpful to optimize 
treatment for patients with TRS and thereby improve treatment outcomes. Utilizing the nationwide 
longitudinal information on all individuals with schizophrenia recorded in Danish registers, we therefore 
aim to assess the association between urbanicity and a treatment-based proxy for TRS. Moreover, we aim 
to evaluate the temporal association between urbanicity and TRS. 
2 Methods 
2.1 Study cohort 
We conducted a population-based cohort study including all individuals born in Denmark after 1955 with 
a first diagnosis of schizophrenia (ICD-10: F20) between January 1, 1996 and July 1, 2013 and aged 18 
years or older. We excluded individuals who received clozapine prior to their first recorded schizophrenia 
diagnosis, or died or emigrated during their first admission to a psychiatric hospital with a schizophrenia 
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diagnosis. We followed individuals from their first diagnosis of schizophrenia until criteria were met for 
TRS, emigration from Denmark, death, or July 1, 2013 (whichever came first). 
2.2 Data sources 
We extracted information on all prescriptions redeemed at a pharmacy from The Danish National 
Prescription Registry, where all drug prescriptions since 1995 have been registered (Kildemoes et al., 
2011). We obtained information on hospital admission dates and diagnoses (WHO International 
Classification of Diseases (ICD) version 8 and 10) both from the Danish Psychiatric Central Research 
Register and from the Danish National Patient Registry (Mors et al., 2011; Lynge et al., 2011). We 
obtained information on sex, date of birth, as well as current and past residence in Denmark from the 
Danish Civil Registration System established in 1968 (Pedersen, 2011). The unique personal 
identification number was used to link individual data across the national registration systems, including 
registers holding socio-demographic information (Jensen and Rasmussen, 2011). 
2.3 Treatment-resistant schizophrenia 
We defined occurrence of TRS from data on prescriptions and psychiatric admissions based on Danish 
treatment guidelines and clinical practice (Damkier et al., 2009, Glenthøj et al., 1998). Our proxy 
definition was adapted from the definition of Kane and colleagues and reflected previous and current 
Danish and international treatment guidelines (National Collaborating Centre for Mental Health (UK), 
2009; Damkier et al., 2009; Kane et al., 1988; Suzuki et al., 2012). In Denmark, clozapine should be 
considered prescribed by the psychiatrist in case of insufficient treatment response for at least two 
antipsychotic medications prescribed as monotherapy. Patients are monitored with weekly ECG during 
dosage titration and ECG monitoring continues once stable dosage has been reached. Weekly blood 
monitoring is required the first 18 weeks after initiation, followed by monthly blood monitoring. In 
epidemiological population-based studies, clozapine is often used as a proxy for TRS. However, 
clozapine is often underprescribed, probably due to the regularly monitorings and the fear of severe side 
effects. Thus, we extended the definition of TRS to include patients meeting eligibility criteria for 
clozapine. Individuals met the TRS proxy criteria at their earliest observed instance of either (1) 
redemption of a clozapine prescription or (2) meeting the eligibility criteria for clozapine, defined as a 
hospital admission with a diagnosis of schizophrenia with evidence of treatment adherence after having 
received two prior antipsychotic monotherapy trials of adequate duration, counted from one year prior to 
the first recorded schizophrenia diagnosis.  
Antipsychotic treatment was defined by prescriptions with ATC codes N05A, excluding N05AN01 
(lithium). See table A1 in supplementary material for more detailed description. 
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2.4 Urbanicity 
The degree of urbanicity – based on place of residence – was classified into three levels: 1) capital area, 
2) provincial area, and 3) rural area, as previously reported (Vassos, 2015; Pedersen, 2006). 
2.5 Statistical methods 
We analyzed the association between levels of urbanicity at time of first diagnosis of schizophrenia and 
time to TRS reporting hazard rate ratios (HR) and 95% confidence intervals (CI) from Cox proportional 
hazards regression analysis. For each sex, time since first diagnosis of schizophrenia was the time scale. 
We calculated estimates in two models; one model only adjusted for age and calendar year of first 
schizophrenia diagnosis, and a model also adjusted for other socio-demographic and disease-related 
baseline factors (Table 1). 
Cumulative incidences were plotted stratified by urbanicity and were based on a competing risks model 
with death as well as emigration from Denmark as a competing event. Ignoring censoring from 
emigration and death may bias the cumulative incidences (Andersen et al., 2012). 
To examine the temporal association between exposure and outcome, we conducted the following 
secondary analyses: First, we estimated the interaction between urbanicity at diagnosis and year since 
diagnosis, i.e. estimates for TRS occurring in different years of follow-up, where the follow-up time was 
split into five one-year calendar-year bands??. Furthermore, we conducted analyses assessing urbanicity 
at various ages from birth to the 18th birthday (age 0, 2, 4, …, 18), and urbanicity assessed in every year 
five years prior to the diagnosis of schizophrenia.  
Please note, that for analyses where urbanicity was assessed at birth or during the first 18 years after birth, 
we restricted the study cohort to individuals born after January 1, 1971 as information on residence was 
not available before 1971 (Pedersen et al., 2006). 
The assumption of proportional hazards for the variables urbanicity and sex was tested by log-log plots 
and by testing for significant time-dependent effects. The log-log plots indicated no major violations of 
the proportional hazards assumptions for urbanicity, but a statistically significant time-dependent effect 
was found for the variable sex. To account for this we allowed different baseline hazards for males and 
females. Moreover, all estimates were adjusted for age and calendar year at first diagnosis. Statistical 
analyses were conducted using Stata version 13 (StataCorp LP, College Station, TX, USA), except for 
cumulative incidences which were calculated and plotted using R Statistical Software version 3.1.2. All 
statistical tests used a two-sided alpha of 5%. All estimates are accompanied by 95% likelihood-ratio 
based confidence intervals. 
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We conducted several sensitivity analyses to investigate the robustness of the results. First, we used the 
more narrow TRS proxy definition of clozapine initiation only. Although clozapine is underprescribed 
and this definition will not capture all being treatment resistant, it is likely to have a high positive 
predictive value since almost all patients on clozapine meet criteria for treatment resistance. Second, to 
account for the fact that more than 50% redeemed antipsychotics prior to their first recorded diagnosis of 
schizophrenia, which may – by definition of the outcome – bias the results, we restricted the analysis to 
individuals who initiated antipsychotics after their first recorded diagnosis of schizophrenia. Third, the 
main analysis was repeated using the following five-level categorization of the urbanicity exposure 
(capital, suburb to the capital, provincial city, provincial town, and rural area).   
Last, all-cause mortality was evaluated as a proxy for disease severity across levels of urbanicity. 
3 Results 
Among the 13,349 individuals with their first schizophrenia diagnosis between January 1, 1996 and July 
1, 2013, a total number of 2313 (17.3%) met at least one of the two criteria for TRS. In particular, 1424 
(10.7%) redeemed at least one clozapine prescription (criterion one) and 1281 (9.6%) were admitted to hospital after 
two periods of different antipsychotic monotherapy (criterion two).Median follow-up was 7 years, inter-quartile 
range: 3-12 years. A significant urban-rural difference in absolute risk of TRS was estimated at 5 and 10 
years after first schizophrenia diagnosis; at 5 years the risk ranged from 10.5% in the capital area to 
17.6% in the rual areas (Figure 1 and Table 2). Distributions of baseline characteristics across levels of 
urbanicity at first diagnosis of schizophrenia are shown in Table 1. Most factors were not equally 
distributed across levels of urbanicity, and in particular a higher prevalence of individuals with prior 
psychotropic medication as well as other medication was present in the provincial and rural areas.   
Table 1 approximately here 
We found a clear association between lower levels of urbanicity (at diagnosis) and increased incidence of 
TRS. Hazard ratio estimates (HR) were (capital area as reference): HR=1.44 (1.31-1.59) for provincial 
areas and HR=1.60 (1.43-1.79) for rural areas (Table 2). The effect sizes remain significant when 
including socio-demographic and disease-related baseline factors in the model (Table 2). 
Table 2 approximately here 
The cumulative incidence of TRS is shown in Figure 2. The cumulative incidence measures the 
probability of meeting the TRS criteria before a given time since the first recorded diagnosis of 
schizophrenia. Figure 2 shows that irrespectively of time since first schizophrenia diagnosis, individuals 
living in less urban areas than the capital have the highest risk of meeting the TRS criteria.  
Commented [CBP5]: Here are some font size problems 
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Figure 1 approximately here 
The effect of urbanicity was even larger when TRS occurred in the first years after the first schizophrenia 
diagnosis and the effect diminished when the TRS criteria was met in later years after diagnosis (Figure 
A1). 
When urbanicity at birth (as opposed to urbanicity at diagnosis) was used as exposure, the rate of TRS 
remained higher in provincial and rural areas compared to the capital area, although with slightly smaller 
effect sizes only reaching statistical significance for the provincial areas: provincial areas, HR=1.19 
(1.05-1.34), rural areas, HR= 1.12 (0.98-1.28). 
The urban-rural differences showed a tendency to diminish slightly when urbanicity was assessed at 
younger age (Figure 2a) or longer before diagnosis of schizophrenia (Figure 2b). 
For the clozapine only definition, similar results were found. When urbanicity was obtained at diagnosis, 
the estimates were (capital area as reference): HR=1.55 (1.36-1.76) for provincial areas and HR=1.63 
(1.41-1.88) for rural areas (Table A3). When urbanicity was obtained at birth, the estimates were: 
HR=1.18 (1.02-1.38), rural areas, HR= 1.17 (0.99-1.38). For urbanicity obtained at different time points 
between birth and diagnosis of schizophrenia, and for TRS occurring in different years after diagnosis, 
similar patterns were seen for the clozapine only definition (Figure A2 and A3).  
Figure 2 approximately here 
Results of sensitivity analyses were only reported for the TRS proxy definition including both those 
initiating clozapine and those meeting eligibility criteria for clozapine. Restricting to individuals only 
initiating antipsychotic treatment after diagnosis of schizophrenia resulted in similar but decreased effect 
sizes for urbanicity at diagnosis (capital area as reference: HR=1.22 (1.03-1.44) for provincial areas and 
HR=1.20 (0.98-1.47) for rural areas) and the years prior to first schizophrenia diagnosis (results not 
shown, available upon request). For urbanicity obtained at birth and during the first 18 years, no relation 
between urbanicity and TRS was found among new users of antipsychotics (results not shown, available 
upon request). 
We repeated the analyses categorizing urbanicity exposure using a more detailed 5-level classification as 
used in a previous study on urbanicity and schizophrenia (Pedersen and Mortensen ,2001b). Estimates 
were (capital as reference): suburb to the capital, HR=1.34 (1.14-1.58), provincial city, HR=1.65 (1.43-
1.91), provincial town, HR=1.60 (1.41-1.82), rural area, HR=1.79 (1.57-2.04).  
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The cumulative incidence of all-cause mortality after the first diagnosis of schizophrenia was largest in 
the capital area, whereas provincial areas had the lowest mortality (Figure A2). 
4 Discussion 
The present study demonstrates that the lower the degree of urbanicity the higher the risk of TRS, 
irrespective of which point in time urbanicity was measured prior to the first diagnosis of schizophrenia. 
Based on the worldwide consistent finding that the higher the degree of urbanicity the higher the risk of 
schizophrenia, our finding was contrary to our expectations. 
Our finding is in accordance with a Danish study showing that individuals treated at university hospitals, 
which are mainly located in the more urban areas of Denmark, are less likely to have clozapine prescribed 
compared to individuals treated at non-university hospitals mainly located in less urban areas (Nielsen et 
al., 2012). Another study on predictors of TRS identified the same association between urbanicity 
obtained at diagnosis and the treatment-based proxy for TRS (Wimberley et al., 2016). 
Using residential information on urbanicity provided us with the rare and unique possibility to evaluate 
the impact of urbanicity on TRS at various time-points, both before and at first diagnosis of 
schizophrenia. We found that urbanicity acted prior to diagnosis of schizophrenia. However, a decreasing 
though still significant effect was observed the earlier urbanicity was measured prior to schizophrenia 
diagnosis, indicating the robustness of the association. With regard to timing of TRS, we only found an 
effect of urbanicity if TRS occurred within the first two years after diagnosis of schizophrenia, with living 
in the capital area being associated with decreased TRS compared to any other level of urbanicity, but the 
effect sizes diminishing with time after diagnosis of schizophrenia. This could to some extent indicate 
earlier recognition of TRS in rural areas.  
4.1 Can regional differences in treatment or diagnostic procedures explain 
urban-rural differences in TRS? 
The results may partly be explained by systematic differences in prescribing practice across different 
levels of urbanicity. Even though baseline characteristics show that individuals living in the capital are 
more likely to have prior schizophrenia-like diagnoses, individuals in rural areas are more likely to 
redeem antipsychotics as well as other psychotropic treatment in the year prior to their first diagnosis of 
schizophrenia. This may introduce a bias whereby individuals living in rural areas are more likely to fulfil 
the treatment-based TRS criteria of having previously unsuccessfully received two or more courses of 
antipsychotic treatment. The effect sizes, however, remained significant though decreased after adjusting 
for prior antipsychotic use and when restricting to new users of antipsychotic treatment. Moreover, the 
association between urbanicity at first schizophrenia diagnosis and TRS persisted even when different 
Commented [CBP6]: I suggest to delete this to ease 
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proxy definitions of TRS were applied. Using hospital and prescription registry data it was not possible to 
investigate why individuals in rural areas initiated antipsychotic treatment earlier than in urban areas, or 
whether alternative non-pharmacological treatment options were offered in the capital area instead. 
Furthermore, previous research found shorter duration of untreated psychosis (DUP) to be associated with 
better prognosis (Harris et al., 2005), and significantly longer DUP was observed in highly urbanized 
areas in the Netherlands (Boonstra et al., 2012). In our study cohort individuals diagnosed with 
schizophrenia were not older in rural areas, indicating that detection of schizophrenia does not seem to be 
delayed in less urban areas. 
Moreover, first-time psychosis patients living in rural areas may to a higher extent – due to less access to 
psychiatric services – be treated by their general practitioners before referral to a psychiatric hospital, 
where the diagnosis of schizophrenia is for the first time being recorded in the hospital register, our 
source of information. By contrast the capital area and the second largest city in Denmark participated in 
an early intervention trial (OPUS) for first-episode psychosis patients, which may have generally affected 
treatment strategies in these areas (Petersen et al., 2005).Individuals in the capital were more likely to 
have a prior schizophrenia-like diagnosis, whereas individuals in rural areas were more likely to have a 
prior diagnosis of bipolar disorder, personality disorder or depression. First, this could indicate 
differences in diagnostic work-up and treatment before the schizophrenia diagnosis is confirmed. Second, 
this could indicate different clinical subtypes of schizophrenia in rural versus urban areas.  
4.2 Is TRS a distinct subtype of schizophrenia? 
Our findings are consistent with an emerging view that TRS is a distinct type of schizophrenia with a 
different aetiology than treatment-responsive schizophrenia, rather than merely representing a more 
severe form of schizophrenia (Nakajima et al., 2015, Sagud, 2015). While urbanicity is a well-established 
risk factor for schizophrenia per se (March et al., 2008; Vassos et al., 2012) it may be that the urban 
excess in schizophrenia applies only to treatment-responsive schizophrenia and does not apply to TRS. In 
other words, the association may be better conceptualised as an excess of treatment-responsive 
schizophrenia in cities as opposed to an excess of treatment-resistant schizophrenia in rural areas. 
4.3 Other potential explanations 
The association between urbanicity and TRS could also theoretically be explained by migration of pre-
schizophrenic or prodromal cases from urban settings to rural areas (Freeman,1994). However, persons 
with schizophrenia in Denmark have recently been shown to migrate towards more urban areas due to the 
development of the disorder or its prodomata (Pedersen, 2015). 
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Another potential explanation includes increased severity of schizophrenia in urban areas as implicated by 
the detected excess mortality of schizophrenia in urban areas. However, even if all persons with 
schizophrenia who lived in the capital at time of first schizophrenia diagnosis and died within 10 years 
were designated as having developed TRS, this would still not have been sufficient to reach the same 
level of cumulative incidence of TRS after 10 years as for those diagnosed in a rural area. 
4.4 Limitations 
Our TRS proxy was defined exclusively from registry data using information on antipsychotic 
redemptions from community pharmacies and psychiatric hospital admissions. This definition cannot 
distinguish so-called treatment resistance from insufficient treatment response and switching to clozapine 
or other antipsychotics due to intolerance or non-adherence. The fact that we do not have information on 
antipsychotic medication during hospitalization implies potential underestimation of the number of 
monotherapy trials and thereby underestimation of treatment-resistant cases defined by our proxy for 
TRS. Furthermore the applied main definition may overestimate the true occurrence of TRS. By contrast, 
clozapine is often used as a proxy for treatment resistance, as it is considered the most effective 
antipsychotic treatment (Harris et al. 2005) and it is the only treatment for TRS with a firm evidence base 
as reflected by official treatment guidelines (National Collaborating Centre for Mental Health (UK), 
2009; Leucht et al., 2013; Damkier et al., 2009). Still, many patients with TRS are not treated with 
clozapine (Howes et al., 2012). We believe that our approach of using clozapine initiation as well as re-
admission while treated after having had two periods of different antipsychotic monotherapies with good 
adherence – although not an exact measure of truly treatment resistance – is the most accurate marker of 
insufficient treatment response that can be obtained from the available data. We found similar results 
when restricting to the clozapine initiation only definition, indicating that the different rates of TRS across 
levels of urbanicity were not restricted to clozapine prescribing or to other antipsychotic use and 
psychiatric admissions.  
4.5 Conclusion 
We observed that the lower the degree of urbanization the higher the risk of TRS. This effect was 
strongest when urbanicity was assessed at time of first diagnosis and when treatment resistance was 
identified shortly after schizophrenia diagnosis. This inverse finding is intriguing in comparison with the 
well-known association that the higher the degree of urbanization the higher the risk of schizophrenia. It 
may indicate systematic differences in treatment practices across different levels of urbanicity, or 
differences in aetiology between treatment-responsive and treatment-resistant schizophrenia.   
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Figure and Table legends and footnotes 
Table 1: Baseline characteristics across levels of urbanicity at first schizophrenia diagnosis. n=13,349. 
a) The distribution differed significantly across levels of urbanicity. 
Table 2: Association between levels of urbanicity at first schizophrenia diagnosis and treatment -resistant 
schizophrenia (TRS). Hazard rate ratios (HR) and absolute 5- and 10-year risks of TRS are presented. All 
estimates are accompanied by 95% confidence intervals.  
a) Adjusted for age and calendar year of first schizophrenia diagnosis, and allowing different baseline hazards for males and 
females. N=13,349. 
b) Adjusted for age and calendar year of first schizophrenia diagnosis, family history of schizophrenia, education, work status, 
marital status, prior suicide attempts, prior diagnosis of schizophrenia spectrum disorder, prior diagnosis o f other psychiatric 
disorders, psychiatric hospitalization in previous year, psychotropic drugs (antidepressants or benzodiazepines) redeemed in 
previous year, and allowing different baseline hazards for males and females. N=12,611. 
c) The absolute risk (or cumulative incidence) of TRS at 5 and 10 years after first diagnosis with schizophrenia 
Figure 1: Cumulative incidence of TRS stratified by level of urbanicity  at first diagnosis of schizophrenia. 
The cumulative incidence measure the probability (or risk) for a person with schizophrenia of meeting TRS 
criteria according to number of years since first schizophrenia diagnosis.   
Figure 2: Hazard ratio estimates for TRS in different models where urbanicity were obtained at different 
time points. (a) Ages after birth, where the cohort is restricted to individuals born after 1971 to have full 
information on residence at time of birth. (b) Years prior to first schizophr enia diagnosis. 
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Main Tables and Figures 
 
Table 1: Baseline characteristics across levels of urbanicity at first schizophrenia diagnosis. n=13,349.  
 Levels of urbanicity at diagnosis  
 
Baseline characteristics (%) 
 
Capital area 
 
Provincial 
areas 
 
Rural areas 
 
Total 
N (%)  4,394 (32.9%) 5,746 (43.0%) 3,209 (24.0%) 13,349 (100%) 
     
Age, median (inter-quartile range)a 28.3 (22.7-36.6) 26.6 (22.1-34.3) 27.5 (21.9-35.9) 27.4 (22.2-35.3) 
Age<25 a  36.1 42.5 41.9 40.3 
Female sex 37.6 39.9 38.8 38.9 
Family history of SZ 8.5 7.2 7.7 7.7 
Education (only primary level) a  57.4 64.9 70.3 63.7 
Work status (early ret. pens.) a 11.1 15.3 17.9 14.5 
Living alone vs. cohabitating a  79.1 76.1 67.2 74.9 
Suicide attempts prior to diagnosis a 16.3 23.4 23.1 21.0 
Prior diagnosis of SZ spectrum disorder a 50.4 39.9 40.5 43.5 
Other prior psychiatric diagnosis than schizophrenia 
(bipolar, depression, personality disorder, autism, 
ADHD) a 
41.6 44.9 47.5 44.4 
Prior diagnosis of substance abuse 32.0 31.2 31.7 31.6 
Psychiatric hosp. in previous year 30.0 27.9 28.6 28.7 
In-patient at first diagnosis  40.6 42.9 42.2 42.0 
Psychotropic drugs (antipsychotics, antidepressants, 
benzodiazepines, or mood stabilizers) redeemed in 
previous year a, b 
56.1 70.5 74.5 66.7 
Any drugs (non-neuroleptics) redeemed in previous 
year a 
56.1 60.8 64.8 60.2 
a) The distribution differed significantly across levels of urbanicity. 
b) Percentages increase across levels of urbanicity for all four classes of psychotropic drugs. Further details on classification of 
drugs can be found in table A2 in the appendix. 
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Table 2: Association between levels of urbanicity at first schizophrenia diagnosis and treatment-resistant 
schizophrenia (TRS). Hazard rate ratios (HR) and absolute 5- and 10-year risks of TRS are presented. All 
estimates are accompanied by 95% confidence intervals.  
 Total Number 
of events 
Incidence Rate per 
100 person-years 
HR and 95% CI for TRS Absolute risk of TRS after first 
diagnosisc 
 
Level of 
urbanicity 
(diagnosis) 
   Model 1a Model 2b 5-year risk 
(%) 
10-year risk 
(%) 
Capital area  4394 608 1.98 (1.83-2.14) 1.00 (ref) 1.00 (ref) 10.5 (9.6-11.6) 15.7 (14.5-17.0) 
Provincial areas 5746 1081 2.98 (2.81-3.16) 1.44 (1.31-1.59) 1.40 (1.26-1.56) 17.3 (16.3-18.4) 22.0 (20.7-23.2) 
Rural areas 3209 624 3.29 (3.04-3.56) 1.60 (1.43-1.79) 1.56 (1.39-1.76) 17.6 (16.1-19.1) 23.1 (21.3-24.9) 
a) Model 1: Adjusted for age and calendar year of first schizophrenia diagnosis, and allowing different baseline hazards for males and females. 
N=13,349. 
b) Model 2: Adjusted for age and calendar year of first schizophrenia diagnosis, family history of schizophrenia, education, work status, marital 
status, prior suicide attempts, prior diagnosis of schizophrenia spectrum disorder, prior diagnosis of other psychiatric disorders, psychiatric 
hospitalization in previous year, drugs (antidepressants, benzodiazepines, or mood stabilizers) redeemed in previous year, and allowing different 
baseline hazards for males and females. N=12,611. 
c) The absolute risk (or cumulative incidence) of TRS at 5 and 10 years after first diagnosis with schizophrenia. To help the average reader I 
suggest to include: Figure 1 contain identical estimates for all time-points from 0 to 10 years since first diagnosis with schizophrenia. 
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Figure 2: Cumulative incidence of TRS stratified by level of urbanicity at first diagnosis of schizophrenia. The 
cumulative incidence measure the probability (or risk) for a person with schizophrenia of meeting TRS criteria 
according to number of years since first schizophrenia diagnosis. Table 1 contain identical estimates at two 
selected time points : 5 year risk and 10 year risk. 
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Figure 2: Hazard ratio estimates for TRS in different models where urbanicity were obtained at different  time 
points. (a) Ages after birth, where the cohort is restricted to individuals born after 1971 to have full information 
on residence at time of birth. (b) Years prior to first schizophrenia diagnosis.  
 
 
 
